SCHEMBL6300267

SCHEMBL6300267

COC(=O)c1c[nH]c(=O)c(N)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.50
ALDH1A1 P00352 9/20 0.50
MAPT P10636 8/20 0.50
HPGD P15428 6/20 0.50
GAA P10253 4/20 0.50
HSD17B10 Q99714 2/20 0.50
CASP1 P29466 2/20 0.50
GLA P06280 1/20 0.50
CASP7 P55210 1/20 0.50
ATM Q13315 1/20 0.50
POLB P06746 2/20 0.44
USP2 O75604 1/20 0.43
BAZ2B Q9UIF8 1/20 0.42
BAZ2A Q9UIF9 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4276880 0.81 KDM4E (0.49) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL31337488 0.80 POLB (0.45) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL14333224 0.80 LMNA (0.55) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL24930955 0.79 ALDH1A1 (0.46) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL544803 0.79 PKM (0.47) KDM4EALDH1A1GAAPOLBBAZ2B
SCHEMBL4538667 0.79 POLB (0.44) KDM4EALDH1A1GAAPOLBBAZ2B
SCHEMBL14333127 0.79 MAPT (0.47) KDM4EALDH1A1MAPTGAAATM
SCHEMBL14333307 0.79 POLB (0.44) KDM4EALDH1A1MAPTGAAPOLB
SCHEMBL924812 0.79 NOTUM (0.45) KDM4EALDH1A1MAPTGAAHSD17B10
SCHEMBL23214997 0.76 ALDH1A1 (0.44) KDM4EALDH1A1MAPTGAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240409527-A1 INHIBITORS OF ALPHA-5 BETA-1 INTEGRIN AND USES THEREOF UNIV CALIFORNIA (US) 2024-12-12 US disclosed
WO-2023060039-A1 INHIBITORS OF ALPHA-5 BETA-1 INTEGRIN AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-04-13 WO disclosed
US-6841559-B1 Pyridinones to treat and prevent bacterial infections WASHINGTON UNIVERSITY OF ST. LOUIS (US) 2005-01-11 US disclosed
EP-1233967-A4 PYRIDINONES TO TREAT AND PREVENT BACTERIAL INFECTIONS UNIV WASHINGTON (US) 2003-07-09 EP disclosed
EP-1233967-A1 PYRIDINONES TO TREAT AND PREVENT BACTERIAL INFECTIONS WASHINGTON UNIVERSITY (US) 2002-08-28 EP disclosed
WO-2001036426-A1 PYRIDINONES TO TREAT AND PREVENT BACTERIAL INFECTIONS WASHINGTON UNIVERSITY (US) 2001-05-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240409527-A1 INHIBITORS OF ALPHA-5 BETA-1 INTEGRIN AND USES THEREOF ITGB5, ITGA5, ITGB1 KDM4E 3248/4885ALDH1A1 282/4885MAPT 3758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.